The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
Sire集團有限公司表示，預計將向泰坦製藥公司提議與KE Sdn進行業務合併。Bhd
- SEC 13D/Amended Filing
-SEC 13D/修正申報
After giving effect to these changes in membership, as of April 2, 2024, four of the board's seven directors had been nominated by the reporting persons. The reporting persons expect to propose to the Issuer a business combination with KE Sdn. Bhd., a Malaysian company. Any such transaction would be subject to execution of definitive documents negotiated between the reporting persons and a committee of independent directors of the Issuer. This report does not constitute an offer of any securities for sale.
在這些成員變更生效後，截至2024年4月2日，董事會的七名董事中有四名已由申報人提名。申報人預計將向發行人提議與KE Sdn進行業務合併。Bhd.，一家馬來西亞公司。任何此類交易都必須執行申報人與發行人獨立董事委員會之間談判的最終文件。本報告不構成任何待售證券的要約。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。